Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz · DE
Area of research
Immunology · Oncology
Research interest
Research interests include Immunotherapy and Immune Responses, CAR-T cell therapy research, RNA Interference and Gene Delivery, and Cancer Immunotherapy and Biomarkers.
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC
Analysis of RBP expression and binding sites identifies PTBP1 as a regulator of CD19 expression in B-ALL
The gut microbiota instructs the hepatic endothelial cell transcriptome
549 An RNA-lipoplex (RNA-LPX) vaccine demonstrates strong immunogenicity and promising clinical activity in a Phase I trial in cutaneous melanoma patients with no evidence of disease at trial inclusion
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer
A shared tumor-antigen RNA-lipoplex vaccine with/without anti-PD1 in patients with checkpoint-inhibition experienced melanoma.
Gating Harmonization Guidelines for Intracellular Cytokine Staining Validated in Second International Multiconsortia Proficiency Panel Conducted by Cancer Immunotherapy Consortium (<scp>CIC</scp>/<scp>CRI</scp>)
Abstract CT156: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Abstract CT034: A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Abstract B041: A novel nanoparticular formulated tetravalent RNA cancer vaccine for treatment of patients with malignant melanoma
Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters
Abstract CT202: IVAC MUTANOME: Individualized vaccines for the treatment of cancer
Improved method to retain cytosolic reporter protein fluorescence while staining for nuclear proteins
Functional TCR Retrieval from Single Antigen-Specific Human T Cells Reveals Multiple Novel Epitopes
Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction
mTOR Inhibition Improves Antitumor Effects of Vaccination with Antigen-Encoding RNA
Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols